Docusign Inc vs 22nd Century Group Inc — how do they compare? Docusign Inc trades at $70.1 (market cap $13.35B), while 22nd Century Group Inc trades at $0.84 (market cap $621.67K). The key difference: Docusign Inc is far larger — about 21474.4× 22nd Century Group Inc's market cap, and Docusign Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and 22nd Century Group Inc for 32 Days on average.
| DOCU | XXII | |
|---|---|---|
Market Cap | $13.35B | $621.67K |
Volume | 3,158,858 | 45,625 |
Sector | Technology | Consumer Staples |
52-Week High | $73.14 | $483.00 |
52-Week Low | $41.75 | $0.80 |
Typical Hold Time | 71 Days | 32 Days |
Enterprise Value | $12.76B | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $68.90, up 1.0% on the day, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. Revenue growth has accelerated to $2.98 billion in 2025, with net income surging to $1.07 billion. The company maintains strong profitability metrics, including a 79.49% gross margin and 17.8% ROE, while recent news highlights AI integration in contract processing and leadership in workflow software.
The outlook is supported by solid fundamentals and positive analyst sentiment, though valuation multiples like a P/E of 43.55 suggest premium pricing. Key risks include market saturation in e-signatures and insider selling activity. The consensus price target of $68.75 aligns closely with the current price, indicating a neutral near-term view with long-term growth potential from AI adoption.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →